Hey Neurohacker,

Before we dive in — a quick but genuine thank you. With 55% of you opening The Neurocircuit every single week, you're not just a subscriber, you're an active part of this community. That means everything to us.

This week, we're asking you to help us go further — together:

🧠 Refer a Neurohacker → Know someone who geeks out over brain optimization, performance, or neuroscience? Send them our way. Refer a Neurohacker 🦾

⚡ Join the Community Challenge → This week's challenge is live. Participate, share your results, and let's grow as a community — because the bigger we get, the bigger the things we can Hack the Neuron on together. Join the Challenge 🧎

📬 Help Shape The Neurocircuit → Got feedback? A topic you want covered? Something we can do better? Tell us. This newsletter is built for you, so help us build it right. Send Feedback 🧑‍💻

And before we get into this week's content — a quick word from our partner:

✦ This Week's Partner: MIintlify

Neurotechnology News | February 28 – March 6, 2026

Let's cut through the noise this week!

This week, peer-reviewed data validated accelerated TMS protocols for depression while CorTec completed its second closed-loop BCI implant for stroke recovery. In industry, Science Corp.'s $230M raise positions it to beat competitors to market with a retinal implant, and Cognito Therapeutics secured $105M for its Alzheimer's neurostimulation platform. Meanwhile, six U.S. states introduced neural data privacy bills in early 2026, signaling regulatory momentum is accelerating alongside commercialization. Bottom line: the field is shifting from "can it work?" to "which architectures survive contact with regulators, payers, and home use?"

Science Corp., founded by former Neuralink president Max Hodak, raised $230 million in Series C funding at a $1.5 billion valuation, bringing total capital to approximately $490 million. The company expects CE mark approval for its PRIMA retinal implant by mid-2026, which would make it the first BCI company with a commercial product — ahead of Neuralink, Synchron, and Paradromics.

Why it stands above the rest: This isn't just another funding round; it's a potential inflection point for the entire BCI sector. PRIMA is architecturally simpler than cortical BCIs — a photovoltaic chip smaller than a grain of rice that sits under the retina rather than penetrating brain tissue. By pursuing European approval first and targeting a tightly-scoped sensory restoration use case (macular degeneration), Science has de-risked the regulatory path while competitors chase broader, harder-to-quantify motor restoration endpoints. From an engineering standpoint, this validates the hypothesis that the first scaled BCI successes may come from narrower clinical workflows with cleaner endpoints — not general-purpose brain control platforms.

Published: March 4, 2026
Read more ➡️Mental Health Network Coverage / BrainsWay Press Release

Two peer-reviewed manuscripts in Brain Stimulation showed BrainsWay's accelerated SWIFT Deep TMS protocol achieved an 87.8% response rate and 78.0% remission rate for major depressive disorder — comparable to standard protocols while reducing acute treatment from 20 visits to 6 half-days. Median time to remission was 21 days versus 28 days for standard care; approximately 60% of patients reached normal-range functioning.

💡 Big Picture: This is a protocol optimization breakthrough, not a hardware one — and that's precisely why it matters. The constraint was never the stimulation technology; it was the delivery architecture. By compressing dosing while maintaining efficacy, BrainsWay has potentially unlocked the scalability that TMS always promised but couldn't deliver operationally.

Published: March 4, 2026 (announcing February procedure)
Read more ➡️ MassDevice Coverage / CorTec Press Release

German neurotechnology company CorTec implanted its Brain Interchange BCI system in a second stroke patient at Harborview Medical Center in Seattle under an FDA Investigational Device Exemption. The fully implantable, closed-loop platform continuously records neural activity and delivers targeted electrical stimulation in real time to enhance neuroplasticity during rehabilitation.

💡 Big Picture: CorTec's bidirectional architecture — recording plus stimulation in one fully implanted system — represents the design most researchers believe will dominate therapeutic BCIs. The fact that a German-manufactured system is advancing through FDA IDE pathways signals that European neurotech isn't ceding the regulatory race.

Published: March 4, 2026
Read more ➡️ WIRED Feature / ClinicalTrials.gov Registry

WIRED profiled Rodney Gorham, an ALS patient who has now lived with Synchron's endovascular BCI for five years — the company's longest-term user. The device has evolved from single-click control toward cursor control and broader home-device interaction, while Synchron continues preparing for a pivotal trial.

💡 Big Picture: This is a durability and workflow story, not just a decoding story. Long-term use is exposing the real system bottlenecks: caregiver setup, wireless reliability, external hardware complexity, and the difficulty of defining clinically meaningful endpoints for assistive BCIs used in the home.

⚠️ Flag: Sourcing relies on feature journalism rather than a new peer-reviewed paper. The news value comes from the five-year milestone and product-learning narrative.

Published: March 3, 2026
Read more ➡️ Medical Xpress Coverage / Nature Neuroscience Paper

Researchers demonstrated that personalized brain-imaging models can decode fluctuations in spontaneous pain intensity in individuals with fibromyalgia. Critically, the models require extensive within-person data; conventional neuroimaging data quantities were insufficient for reliable predictions, and neural patterns of pain were highly individualized.

💡 Big Picture: This is a data architecture finding with broad implications: population-level brain biomarkers for subjective states like pain may be fundamentally limited. The path forward is individualized models requiring dense longitudinal sampling — a completely different infrastructure requirement than current neuroimaging paradigms.

Published: March 5, 2026
Read more ➡️ Medical Device Network / PR Newswire Release

Neuspera announced its integrated sacral neuromodulation system showed positive 12-month pivotal results for urinary urge incontinence, including strong responder rates and no serious device-related adverse events. The company also reported shorter daily stimulation regimens may be possible.

💡 Big Picture: Neuromodulation platforms are now competing not just on efficacy, but on implant burden, daily wear burden, and how much hardware can be pushed off-board without losing reliability — a miniaturization and therapy-burden story.

⚠️ Flag: Results from company disclosure and trade coverage; not yet peer-reviewed in-window.

Published: March 5, 2026
Read more ➡️ TechCrunch Coverage / Cooley LLP Press Release

Science Corporation closed a $230 million Series C with investors including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital. The company expects CE mark approval for its PRIMA retinal implant by mid-2026, with Germany likely as first market; FDA discussions are ongoing.

💡 Big Picture: Science's acquisition-then-optimize strategy (buying PRIMA assets from Pixium Vision in 2024) combined with European-first regulatory arbitrage could establish commercial precedent before Neuralink's more ambitious cortical approach clears FDA.

Published: March 5, 2026
Read more ➡️ MobiHealthNews Coverage / Cognito Press Release

Cognito announced an oversubscribed $105 million Series C to advance Spectris, its visual-and-auditory stimulation platform targeting Alzheimer's disease. The non-invasive, home-deployable system uses sensory stimulation to target neural circuits implicated in neurodegeneration.

💡 Big Picture: Cognito occupies an architecturally attractive middle ground: more scalable than implants, more medically serious than wellness EEG, and potentially easier to distribute at scale if efficacy holds under real-world use.

Published: March 3, 2026
Read more ➡️ Behavioral Health Business / Company Press Release

Salma Health emerged from stealth with $80 million in Series A funding to open integrated brain health clinics combining psychiatric care, neurological services, clinical trials access, and AI-driven diagnostics in initial California locations.

💡 Big Picture: This signals a shift toward scalable, closed-loop neurotech ecosystems that integrate hardware, software, and clinical data flows — potentially solving interoperability challenges in fragmented brain health systems while accelerating prototype validation through real-world deployments.

Published: March 1, 2026
Read more ➡️ Company Press Release

Pharaoh Neuro raised $45 million in Series B funding to advance its implantable neuromodulation device for chronic pain, with plans for expanded clinical deployments following positive early trial data.

💡 Big Picture: The funding underscores progress in miniaturized, adaptive neuromodulation hardware, addressing power efficiency and signal fidelity issues in long-term implants — system architecture challenges that define competitive positioning in disease-specific neurostimulation.

Published: February 23, 2026 (analysis of bills introduced through early March)
Read more ➡️ Risk Management Magazine Analysis / Cooley LLP Legal Analysis

In the first six weeks of 2026, nine bills regulating neural data were introduced across Alabama, California, Illinois, New York, Vermont, and Virginia. Some bills (Illinois SB 2994, HB 5179; Vermont HB 814) provide individuals with a private right of action. Definitions vary: Illinois carves out "nonneural information" like pupil dilation; Vermont introduces "conscious bypass" into statutory language.

💡 Big Picture: The regulatory substrate is forming before mass commercial deployment, not after. For neurotech companies, this creates compliance complexity but also forces data governance architecture decisions now — build it in, or retrofit it later at much higher cost.

Published: Enacted 2025, effective July 1, 2026
Read more ➡️ Inside Privacy / Future of Privacy Forum Analysis

Connecticut SB 1295 amends the Connecticut Data Privacy Act to classify "neural data" — defined as information generated by measuring central nervous system activity — as "sensitive data" requiring heightened protections. Connecticut joins California, Colorado, and Montana with enacted neural data laws.

💡 Big Picture: Companies shipping EEG-based consumer devices, clinical BCIs, or research tools into these states now need audit trails demonstrating how neural data flows through their systems.

Published: March 5, 2026
Read more ➡️ Reuters Coverage / 2026 Government Work Report

China's new five-year policy blueprint placed brain–machine interfaces among the "industries of the future" alongside AI, quantum, and 6G. The plan emphasizes frontier R&D, funding mechanisms, talent cultivation, and infrastructure build-out for neurotechnology.

💡 Big Picture: This is a full-stack industrial-policy signal. Neurotech progress depends not just on better electrodes or models, but on supply chains, translational funding, hospital capacity, standards, and domestic manufacturing. BCIs are now being treated as a strategic platform technology, not a niche medical-device category.

The Consent Architecture Problem in Closed-Loop BCIs

This week's stories highlight a tension that current frameworks weren't designed to handle. Closed-loop BCIs that both record and stimulate create novel consent questions: when a system "delivers targeted electrical stimulation in real time" based on "continuously recorded and interpreted neural activity," the patient cannot fully know in advance what stimulation patterns they'll receive.

Meanwhile, proliferating state neural data laws treat neural data as something to be collected, stored, and potentially deleted. But what happens when neural data isn't just collected — when it's the real-time control signal for therapeutic stimulation? Can you meaningfully "delete" neural patterns that have already triggered intervention? Does "consent to collection" cover consent to real-time algorithmic interpretation and response?

The engineering architecture of bidirectional BCIs has outpaced the consent architecture. What would technically-informed consent frameworks look like for systems where the intervention and the monitoring are inseparable?

Last month, 48% of visitors to documentation sites across Mintlify were AI agents—not humans.

Claude Code, Cursor, and other coding agents are becoming the actual customers reading your docs. And they read everything.

This changes what good documentation means. Humans skim and forgive gaps. Agents methodically check every endpoint, read every guide, and compare you against alternatives with zero fatigue.

Your docs aren't just helping users anymore—they're your product's first interview with the machines deciding whether to recommend you.

That means:
→ Clear schema markup so agents can parse your content
→ Real benchmarks, not marketing fluff
→ Open endpoints agents can actually test
→ Honest comparisons that emphasize strengths without hype

In the agentic world, documentation becomes 10x more important. Companies that make their products machine-understandable will win distribution through AI.

Make Your Docs Agent-Ready

Neurotech moves faster when people share what they're building. Whether you're working on a DIY biosignal project, following a clinical trial, or just had an idea you can't shake — put it out there. The best thinking in this field happens in the open.

Why bother? This community is small enough that your work actually gets seen, and focused enough that the people seeing it are the right ones. One post can get you a collaborator, a citation, or a conversation that changes the direction of a project.

If this issue made you think of a colleague, a researcher, a builder, or just someone who's been asking the right questions about neurotech — send it their way. The NeuroCircuit grows entirely through word of mouth, and every new reader makes the community sharper.

Share your referral link and earn:

Every issue gets shaped by what readers actually find useful. If something landed well, felt thin, or missed the mark entirely — say so. This is a small, focused publication and your feedback has a direct line to next week's issue.

What's worth a minute of your time: